ELCC Updates in Immunotherapy and Beyond for Non–Small Cell Lung Cancer : Episode 5

Video

May 9, 2023

Data Updates on Single-Agent Immunotherapy in Advanced NSCLC

Author(s):

Jarushka Naidoo, MD, M.B.B.Ch.,Solange Peters, MD, PhD

Experts explain recent data updates on single-agent immunotherapy treatment for patient with advanced NSCLC.

EP: 1.Overview of PD-L1 Testing in Advanced NSCLC

EP: 2.Subgrouping Patients with Advanced NSCLC for Tailored Treatment

EP: 3.CTLA-4 Targeted Regimens in Advanced NSCLC

EP: 4.Updates in Gender-Based Treatment for Patients with Advanced NSCLC

Now Viewing

EP: 5.Data Updates on Single-Agent Immunotherapy in Advanced NSCLC

EP: 6.Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC

EP: 7.Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC

EP: 8.Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial

EP: 9.Combination Chemotherapy and Immunotherapy for Advanced NSCLC

EP: 10.The Evolution of Chemoimmunotherapy in Advanced NSCLC

Sponsored in part by Regeneron. Content independently created by OncLive.

Related Content

Lung cancer, Image credit: Axel Kock – stock.adobe.com

November 20th 2024

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

November 19th 2024

Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC

October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

November 18th 2024

Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC

November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10